CXCR4-Targeted Nanotherapeutics: A Promising Approach for Liver Fibrosis and Hepatocellular Carcinoma Management

Area of Science:

• Oncology
• Hepatology
• Nanomedicine

Background:

• The CXCR4/CXCL12 axis is crucial in liver fibrosis (LF) pathogenesis, promoting hepatic stellate cell (HSC) activation, inflammation, and angiogenesis.
• In hepatocellular carcinoma (HCC), CXCR4 signaling fuels tumor cell proliferation, survival, and metastasis, linking chronic liver injury to cancer progression.

Purpose of the Study:

• To review the role of the CXCR4/CXCL12 axis in liver fibrosis and hepatocellular carcinoma.
• To explore CXCR4 as a therapeutic target and examine CXCR4-targeted nanotherapeutic strategies for LF and HCC management.

Main Methods:

• Review of literature on CXCR4/CXCL12 interactions, signaling pathways, and their involvement in LF and HCC.
• Analysis of CXCR4-targeted therapies including blockers, peptide inhibitors, gene silencing/editing, and nanotherapeutics (liposomes, NPs, microbubbles).
• Examination of clinical progress of CXCR4-targeting agents (monoclonal antibodies, small molecules, peptides) in preclinical and clinical trials.

Main Results:

• CXCR4 plays a pivotal role in HSC activation, ECM deposition, and scar formation in LF.
• CXCR4 signaling supports HCC proliferation, survival, and metastasis.
• Various CXCR4-targeted nanotherapeutic strategies show potential for LF and HCC treatment.

Conclusions:

• CXCR4 is a critical therapeutic target for both liver fibrosis and hepatocellular carcinoma.
• CXCR4-targeted nanotherapeutics, including liposomes, NPs, and microbubbles, offer a promising approach for managing LF and HCC with improved efficacy and reduced toxicity.